Guardant Health projected material screening revenue growth for 2026 and disclosed the acquisition of MCED startup MetaSight Diagnostics for $59 million upfront (plus up to $90 million contingent). The company expects Shield screening revenue to rise to $162–$174 million in 2026 and volumes to reach 210,000–225,000 tests. Guardant said Shield — its FDA-cleared colorectal cancer screening blood test — benefited from growing demand, strong adherence, and forthcoming integrations with major lab networks, including a commercial collaboration with Quest Diagnostics. The MetaSight purchase expands Guardant’s screening portfolio and technology stack for early-detection assays. Management tempered expectations as early-stage launches scale, but positioned the moves as a deliberate push to build a multi-test screening franchise tied to clinical guideline adoption and payer coverage.